DRIEHAUS CAPITAL MANAGEMENT LLCDRIEHAUS CAPITAL MANAGEMENT LLC

Institutional investor · Portfolio as of Q1 2022

SEC EDGAR SourceSEC Filings

Top Holdings377 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

3.8M$394.8M4.8%$53.95+85.72%
13 qtrssince 2019-Q1
Increased
58

CAMECO CORP

5M$146.2M1.8%$23.70+21.59%
3 qtrssince 2021-Q3
Increased
64

RELAY THERAPEUTICS INC

4.1M$121.2M1.5%$35.80-14.36%
7 qtrssince 2020-Q3
Increased
47
IBNIBN
ADR

ICICI BANK LTD-SPON ADR

6.3M$119.5M1.5%$13.66+34.44%
13 qtrssince 2019-Q1
Decreased
0

CRINETICS PHARMACEUTICALS IN

4.9M$108.5M1.3%$21.19-10.33%
8 qtrssince 2020-Q2
Increased
49

SPRINGWORKS THERAPEUTICS INC

1.8M$104M1.3%
11 qtrssince 2019-Q3
Increased
49

XENON PHARMACEUTICALS INC

3.3M$100.9M1.2%$23.95+25.78%
9 qtrssince 2020-Q1
Increased
50
HDBHDB
ADR

HDFC BANK LTD-ADR

1.5M$92.5M1.1%$28.04+2.16%
13 qtrssince 2019-Q1
Increased
48

AXCELIS TECHNOLOGIES INC

1.2M$90.5M1.1%$51.78+49.56%
5 qtrssince 2021-Q1
Decreased
0

WILLSCOT HOLDINGS CORP

2.3M$89.7M1.1%$35.62+10.99%
3 qtrssince 2021-Q3
Increased
55

MATADOR RESOURCES CO

1.6M$86.5M1.1%$28.72+69.88%
6 qtrssince 2020-Q4
Increased
70
INFYINFY
ADR

INFOSYS LIMITED

3.4M$85.8M1.1%$20.61-43.61%
6 qtrssince 2020-Q4
Increased
56

INSPIRE MED SYS INC

315,387$81M1.0%$161.45+59.80%
13 qtrssince 2019-Q1
Increased
48

MP MATERIALS CORP

1.4M$78.3M1.0%$37.31+51.16%
6 qtrssince 2020-Q4
Increased
46

NEWMONT MINING CORP

915,351$72.7M0.9%$71.330.00%
1 qtr
New
58

GOLDEN ENTERTAINMENT INC

1.2M$71.2M0.9%$35.84+41.88%
6 qtrssince 2020-Q4
Increased
48

CYTOKINETICS INC

1.9M$69.5M0.9%$12.27+197.76%
12 qtrssince 2019-Q2
Decreased
0

TRIUMPH FINANCIAL INC

684,700$64.4M0.8%$50.85+87.70%
11 qtrssince 2019-Q3
Decreased
0

UNITED PARKS & RESORTS INC

862,320$64.2M0.8%$60.48-26.51%
5 qtrssince 2021-Q1
Increased
52
EPIEPI
ETF

WISDOMTREE TR

1.8M$63.3M0.8%$24.58+38.14%
12 qtrssince 2019-Q2
Decreased
0
$8.1B
AUM
377
Positions
Q1 2022
Filing
Rating · 2.0
Quarterly Portfolio Change
+27%Q4'20$6.2B+10%Q1'21$6.8B+11%Q2'21$7.5B+12%Q3'21$8.4B+16%Q4'21$9.8B-17%Q1'22$8.1B
Activity profile
$ moved · Q1'22
New27%Increased14%Decreased37%Exited22%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.4 years
<1Q16%1-4Q28%1-2Y17%2Y+39%

DRIEHAUS CAPITAL MANAGEMENT LLC manages $8.1B across 377 positions as of Q1 2022. Top holdings: TSM (4.8%), CCJ (1.8%), RLAY (1.5%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.

Q1 2022 Summary

Active quarter - 110 new positions, 97 exits, 86 increased. Top move: MTDR (INCREASED, conviction 70). Portfolio: $8.1B across 377 positions.

Top holdings by portfolio weight

Total AUM$8B
TSM4.85%
CCJ1.80%
RLAY1.49%
IBN1.47%
CRNX1.33%
SWTX1.28%
XENE1.24%
HDB1.14%
ACLS1.11%
WSC1.10%
Other1.06%

Portfolio allocation by GICS sector

Sectors11
Unknown17.29%
Technology17.25%
Healthcare15.36%
Industrials11.95%
Consumer Cyclical10.89%
Financial Services7.76%
Energy7.49%
Basic Materials5.37%
Consumer Defensive3.31%
Communication Services2.82%
Other0.51%

Behavioral investing profile

Checking access…
Momentum Trader- primarily Unknown, Technology, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record65
Conviction43
Concentration25
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
EWTXEWTXEDGEWISE THERAPEUTICS INC
Q2 2025 Q2 2026+3.4M shares+$161.9M
5Q
IMAXIMAXIMAX CORP
Q2 2025 Q2 2026+1.9M shares+$82.1M
4Q
IMNMIMNMIMMUNOME INC
Q3 2025 Q2 2026+4.1M shares+$90M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used